SynchNeuro

SynchNeuro operates at the intersection of medical devices, neuroscience software, digital health, and clinical research. Its differentiated thesis is to use EEG-derived brain activity as an input for two applications: synchronizing transcranial magnetic stimulation with brain rhythms and estimating glucose or other metabolic measures without blood sampling. That combination gives the company a distinct technical narrative, but it also creates a broad validation burden across neuromodulation, diagnostics, clinical evidence, and regulatory compliance. In glucose monitoring, it approaches a market dominated by sensor-based platforms from Abbott and Dexcom, where a behind-the-ear, EEG-based approach could reduce the need for skin-penetrating or disposable glucose sensors if accuracy and clinical utility are demonstrated. SynchNeuro’s current position appears exploratory and research-oriented rather than commercially scaled: it has a small disclosed team, no documented financing history, and product claims explicitly dependent on clinical evidence and regulatory authorization. Its main potential differentiation is the integration of brain-signal acquisition, machine learning, individualized treatment planning, and clinical data workflows.

SynchNeuro’s trajectory shows a shift from a focused neurotechnology platform toward a broader brain-based digital-health portfolio. Founded on Jan 1, 2021, the company initially emphasized EEG-guided neuromodulation: hardware and software intended to synchronize TMS with brain activity, support individualized treatment planning, and document clinical or research sessions. Leadership expanded from founder and chairman Casey Halpern, whose role began in August 2021, to president and co-founder Emily Mirro in August 2022 and chief science officer Heonsoo Lee in February 2024. The most significant product inflection point came on Nov 17, 2025, when SynchNeuro introduced a behind-the-ear EEG wearable paired with a mobile application for glucose insights, forecasts, sleep monitoring, and other metabolic metrics. The planned $10 monthly price indicates an attempt to frame the technology as an accessible consumer or hybrid digital-health service rather than solely as clinical infrastructure. With an indicated team size of one to ten employees, growth remains technically ambitious but commercially unproven. The next meaningful inflection points would likely be clinical validation, regulatory progress, and evidence of adoption.